New York State Common Retirement Fund Acquires 93,267 Shares of LivaNova PLC $LIVN

New York State Common Retirement Fund increased its position in shares of LivaNova PLC (NASDAQ:LIVN) by 107.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 180,008 shares of the company’s stock after acquiring an additional 93,267 shares during the period. New York State Common Retirement Fund owned approximately 0.33% of LivaNova worth $9,429,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. State of Wyoming purchased a new stake in LivaNova during the 2nd quarter valued at about $31,000. EverSource Wealth Advisors LLC raised its holdings in LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares during the last quarter. Bayforest Capital Ltd boosted its position in LivaNova by 44.8% during the 3rd quarter. Bayforest Capital Ltd now owns 918 shares of the company’s stock valued at $48,000 after buying an additional 284 shares during the period. GAMMA Investing LLC grew its holdings in LivaNova by 90.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,202 shares of the company’s stock worth $63,000 after acquiring an additional 572 shares during the last quarter. Finally, Strs Ohio bought a new stake in shares of LivaNova in the first quarter worth about $130,000. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

LIVN has been the subject of several research analyst reports. Robert W. Baird set a $75.00 price objective on LivaNova in a report on Tuesday, December 16th. The Goldman Sachs Group reiterated a “neutral” rating and set a $66.00 target price on shares of LivaNova in a research note on Friday, January 9th. Mizuho raised their price target on LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a research note on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, LivaNova has an average rating of “Moderate Buy” and an average target price of $69.38.

LivaNova Price Performance

NASDAQ:LIVN opened at $65.93 on Wednesday. The stock has a market capitalization of $3.60 billion, a PE ratio of -16.48 and a beta of 0.97. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $67.92. The stock’s 50-day moving average price is $63.27 and its 200-day moving average price is $56.35. The company has a quick ratio of 1.12, a current ratio of 1.33 and a debt-to-equity ratio of 0.30.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.